Tandem Diabetes Care (TNDM) Reaches New 52-Week High and Low at $17.64

Tandem Diabetes Care Inc (NASDAQ:TNDM) reached a new 52-week high and low on Tuesday . The company traded as low as $17.64 and last traded at $17.63, with a volume of 93439 shares. The stock had previously closed at $16.63.

Several equities research analysts have recently commented on TNDM shares. Oppenheimer started coverage on shares of Tandem Diabetes Care in a research note on Monday, February 26th. They issued a “buy” rating and a $6.00 target price on the stock. Citigroup started coverage on shares of Tandem Diabetes Care in a research note on Tuesday, February 27th. They issued an “outperform” rating and a $5.50 target price on the stock. Cowen restated a “hold” rating on shares of Tandem Diabetes Care in a research note on Tuesday, February 27th. ValuEngine downgraded shares of Tandem Diabetes Care from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target on shares of Tandem Diabetes Care in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $9.32.

The stock has a market capitalization of $817.61 million, a PE ratio of -1.40 and a beta of -0.10. The company has a debt-to-equity ratio of 6.45, a quick ratio of 2.01 and a current ratio of 2.62.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, April 26th. The medical device company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.44). The company had revenue of $27.30 million for the quarter, compared to analyst estimates of $25.32 million. The firm’s quarterly revenue was up 43.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.75) EPS. equities research analysts expect that Tandem Diabetes Care Inc will post -1.47 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. Acuta Capital Partners LLC bought a new stake in Tandem Diabetes Care during the 1st quarter worth about $6,678,000. Federated Investors Inc. PA increased its stake in shares of Tandem Diabetes Care by 714,273.3% in the 1st quarter. Federated Investors Inc. PA now owns 2,250,276 shares of the medical device company’s stock valued at $11,161,000 after acquiring an additional 2,249,961 shares during the last quarter. Gabelli Funds LLC bought a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at about $102,000. Frontier Capital Management Co. LLC increased its stake in Tandem Diabetes Care by 475.8% during the 1st quarter. Frontier Capital Management Co. LLC now owns 2,720,937 shares of the medical device company’s stock worth $13,496,000 after purchasing an additional 2,248,382 shares in the last quarter. Finally, Westfield Capital Management Co. LP bought a new stake in Tandem Diabetes Care during the 1st quarter worth approximately $378,000. Institutional investors and hedge funds own 47.09% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply